Global Prothrombin Complex Concentrate (PCC) Drug Supply, Demand and Key Producers, 2026-2032
Description
The global Prothrombin Complex Concentrate (PCC) Drug market size is expected to reach $ 2944 million by 2032, rising at a market growth of 10.1% CAGR during the forecast period (2026-2032).
Prothrombin Complex Concentrate (PCC) drugs are plasma-derived, multi-factor coagulation products purified and viral-inactivated from human plasma. They primarily contain four vitamin K-dependent clotting factors—II, VII, IX, and X—and may also include natural anticoagulants such as protein C and protein S. PCC drugs are indicated for the treatment or prevention of bleeding caused by deficiencies in these factors, particularly in cases of warfarin overdose, severe liver dysfunction, or congenital coagulation disorders. Compared with traditional fresh frozen plasma, PCC offers faster onset of action, lower infusion volumes, and reduced infection risks, making it widely used in emergency anticoagulation reversal, surgical hemostasis, and critical bleeding management. With the growing number of patients on anticoagulant therapy and rising surgical and trauma care needs, PCC drugs are emerging as one of the fastest-growing segments in the global plasma-derived therapeutics market.In 2024, global Prothrombin Complex Concentrate (PCC) drugs production reached approximately 4.73 m units, with an average global market price of around US$ 280 perunit.The average gross profit margin of this product is 80%.
The expansion of the PCC drug market is driven by the growing clinical demand and the increasing reliance of healthcare systems on rapid hemostatic solutions. The rising prevalence of patients on anticoagulant therapy—especially those with atrial fibrillation, deep vein thrombosis, or valvular heart disease—has created significant demand for effective reversal agents. Furthermore, PCC’s rapid hemostatic effect in high-risk surgical procedures such as trauma, neurosurgery, and cardiothoracic operations has established it as a critical emergency medicine. New-generation four-factor PCCs are now recommended over three-factor formulations due to their superior efficacy in reversing warfarin effects. Meanwhile, technological advancements in viral inactivation, nanofiltration, and lyophilization have markedly enhanced product safety and stability, boosting market adoption worldwide.
Despite strong growth prospects, the PCC drug industry faces several structural challenges. The supply of human plasma remains constrained and highly regulated, with geographical concentration creating vulnerability to supply chain disruptions. Additionally, the risk of thrombosis associated with high-dose or repeated PCC administration imposes clinical caution. The long production cycle, complex cost structure, and high technical barriers also create significant entry challenges for new manufacturers. In some regions, the preference for lower-cost alternatives such as fresh frozen plasma or recombinant coagulation factors slows PCC adoption. Moreover, variations in national regulatory frameworks and blood product standards may further complicate global market expansion and compliance efforts.
The downstream demand for PCC drugs is becoming increasingly diversified. While traditionally used for warfarin reversal and management of severe bleeding, recent years have seen expanded indications, including bleeding associated with direct oral anticoagulants (DOACs), liver disease-related coagulopathy, perioperative anticoagulant reversal, and obstetric hemorrhage. National clinical guidelines have progressively positioned PCC as a first-line therapy for anticoagulation reversal, accelerating its adoption. In developed markets, PCC use has extended from intensive care units to emergency and general wards. In emerging economies, government healthcare programs and local plasma fractionation initiatives are driving broader market penetration. Looking ahead, standardized hospital inventory practices, emergency medicine training, and combined therapeutic protocols involving PCC and other hemostatic agents will further broaden its clinical scope.
The production of PCC drugs relies heavily on human plasma as the primary biological raw material. Its quality, supply stability, and regulatory compliance directly determine production capacity and product safety standards. Most plasma collection currently occurs in North America and Europe, where mature donor networks and traceable oversight systems are in place. With gradual policy liberalization, Asian countries such as China and India are emerging as new sources of plasma supply growth. In addition to plasma, the upstream chain involves critical components such as viral inactivation reagents, chromatographic media, and lyophilization equipment. While technological advances have improved yield and purity, the stringent ethical and regulatory constraints on plasma sourcing and international transport remain key bottlenecks in the global PCC supply chain.
This report studies the global Prothrombin Complex Concentrate (PCC) Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Prothrombin Complex Concentrate (PCC) Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Prothrombin Complex Concentrate (PCC) Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Prothrombin Complex Concentrate (PCC) Drug total production and demand, 2021-2032, (K Units)
Global Prothrombin Complex Concentrate (PCC) Drug total production value, 2021-2032, (USD Million)
Global Prothrombin Complex Concentrate (PCC) Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Prothrombin Complex Concentrate (PCC) Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Prothrombin Complex Concentrate (PCC) Drug domestic production, consumption, key domestic manufacturers and share
Global Prothrombin Complex Concentrate (PCC) Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Prothrombin Complex Concentrate (PCC) Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Prothrombin Complex Concentrate (PCC) Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Prothrombin Complex Concentrate (PCC) Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, RAAS, Hualan Bio, BOHUI, NUOYI BIO, SINOPHARM, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Prothrombin Complex Concentrate (PCC) Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Prothrombin Complex Concentrate (PCC) Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Type:
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Usage Type:
Lyophilized Powder Form
Liquid Injection Form
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Manufacturing Process:
Plasma-Derived
Recombinant Bioengineered
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Application:
Hemophilia B
Acquired Coagulation Factor Deficiency
Companies Profiled:
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
RAAS
Hualan Bio
BOHUI
NUOYI BIO
SINOPHARM
Guangdong Weilun
Weiguang Bio
Kangbo Bio
Huarun Boya
Taibang Biologic
Key Questions Answered:
1. How big is the global Prothrombin Complex Concentrate (PCC) Drug market?
2. What is the demand of the global Prothrombin Complex Concentrate (PCC) Drug market?
3. What is the year over year growth of the global Prothrombin Complex Concentrate (PCC) Drug market?
4. What is the production and production value of the global Prothrombin Complex Concentrate (PCC) Drug market?
5. Who are the key producers in the global Prothrombin Complex Concentrate (PCC) Drug market?
6. What are the growth factors driving the market demand?
Prothrombin Complex Concentrate (PCC) drugs are plasma-derived, multi-factor coagulation products purified and viral-inactivated from human plasma. They primarily contain four vitamin K-dependent clotting factors—II, VII, IX, and X—and may also include natural anticoagulants such as protein C and protein S. PCC drugs are indicated for the treatment or prevention of bleeding caused by deficiencies in these factors, particularly in cases of warfarin overdose, severe liver dysfunction, or congenital coagulation disorders. Compared with traditional fresh frozen plasma, PCC offers faster onset of action, lower infusion volumes, and reduced infection risks, making it widely used in emergency anticoagulation reversal, surgical hemostasis, and critical bleeding management. With the growing number of patients on anticoagulant therapy and rising surgical and trauma care needs, PCC drugs are emerging as one of the fastest-growing segments in the global plasma-derived therapeutics market.In 2024, global Prothrombin Complex Concentrate (PCC) drugs production reached approximately 4.73 m units, with an average global market price of around US$ 280 perunit.The average gross profit margin of this product is 80%.
The expansion of the PCC drug market is driven by the growing clinical demand and the increasing reliance of healthcare systems on rapid hemostatic solutions. The rising prevalence of patients on anticoagulant therapy—especially those with atrial fibrillation, deep vein thrombosis, or valvular heart disease—has created significant demand for effective reversal agents. Furthermore, PCC’s rapid hemostatic effect in high-risk surgical procedures such as trauma, neurosurgery, and cardiothoracic operations has established it as a critical emergency medicine. New-generation four-factor PCCs are now recommended over three-factor formulations due to their superior efficacy in reversing warfarin effects. Meanwhile, technological advancements in viral inactivation, nanofiltration, and lyophilization have markedly enhanced product safety and stability, boosting market adoption worldwide.
Despite strong growth prospects, the PCC drug industry faces several structural challenges. The supply of human plasma remains constrained and highly regulated, with geographical concentration creating vulnerability to supply chain disruptions. Additionally, the risk of thrombosis associated with high-dose or repeated PCC administration imposes clinical caution. The long production cycle, complex cost structure, and high technical barriers also create significant entry challenges for new manufacturers. In some regions, the preference for lower-cost alternatives such as fresh frozen plasma or recombinant coagulation factors slows PCC adoption. Moreover, variations in national regulatory frameworks and blood product standards may further complicate global market expansion and compliance efforts.
The downstream demand for PCC drugs is becoming increasingly diversified. While traditionally used for warfarin reversal and management of severe bleeding, recent years have seen expanded indications, including bleeding associated with direct oral anticoagulants (DOACs), liver disease-related coagulopathy, perioperative anticoagulant reversal, and obstetric hemorrhage. National clinical guidelines have progressively positioned PCC as a first-line therapy for anticoagulation reversal, accelerating its adoption. In developed markets, PCC use has extended from intensive care units to emergency and general wards. In emerging economies, government healthcare programs and local plasma fractionation initiatives are driving broader market penetration. Looking ahead, standardized hospital inventory practices, emergency medicine training, and combined therapeutic protocols involving PCC and other hemostatic agents will further broaden its clinical scope.
The production of PCC drugs relies heavily on human plasma as the primary biological raw material. Its quality, supply stability, and regulatory compliance directly determine production capacity and product safety standards. Most plasma collection currently occurs in North America and Europe, where mature donor networks and traceable oversight systems are in place. With gradual policy liberalization, Asian countries such as China and India are emerging as new sources of plasma supply growth. In addition to plasma, the upstream chain involves critical components such as viral inactivation reagents, chromatographic media, and lyophilization equipment. While technological advances have improved yield and purity, the stringent ethical and regulatory constraints on plasma sourcing and international transport remain key bottlenecks in the global PCC supply chain.
This report studies the global Prothrombin Complex Concentrate (PCC) Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Prothrombin Complex Concentrate (PCC) Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Prothrombin Complex Concentrate (PCC) Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Prothrombin Complex Concentrate (PCC) Drug total production and demand, 2021-2032, (K Units)
Global Prothrombin Complex Concentrate (PCC) Drug total production value, 2021-2032, (USD Million)
Global Prothrombin Complex Concentrate (PCC) Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Prothrombin Complex Concentrate (PCC) Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Prothrombin Complex Concentrate (PCC) Drug domestic production, consumption, key domestic manufacturers and share
Global Prothrombin Complex Concentrate (PCC) Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Prothrombin Complex Concentrate (PCC) Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Prothrombin Complex Concentrate (PCC) Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Prothrombin Complex Concentrate (PCC) Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, RAAS, Hualan Bio, BOHUI, NUOYI BIO, SINOPHARM, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Prothrombin Complex Concentrate (PCC) Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Prothrombin Complex Concentrate (PCC) Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Type:
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Usage Type:
Lyophilized Powder Form
Liquid Injection Form
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Manufacturing Process:
Plasma-Derived
Recombinant Bioengineered
Global Prothrombin Complex Concentrate (PCC) Drug Market, Segmentation by Application:
Hemophilia B
Acquired Coagulation Factor Deficiency
Companies Profiled:
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
RAAS
Hualan Bio
BOHUI
NUOYI BIO
SINOPHARM
Guangdong Weilun
Weiguang Bio
Kangbo Bio
Huarun Boya
Taibang Biologic
Key Questions Answered:
1. How big is the global Prothrombin Complex Concentrate (PCC) Drug market?
2. What is the demand of the global Prothrombin Complex Concentrate (PCC) Drug market?
3. What is the year over year growth of the global Prothrombin Complex Concentrate (PCC) Drug market?
4. What is the production and production value of the global Prothrombin Complex Concentrate (PCC) Drug market?
5. Who are the key producers in the global Prothrombin Complex Concentrate (PCC) Drug market?
6. What are the growth factors driving the market demand?
Table of Contents
123 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Usage Type
- 7 Market Analysis by Manufacturing Process
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
